Dalezis, P.; Geromichalou, E.; Polonifi, A.; Sagredou, S.; Nikoleousakos, N.; Nikolaou, M.; Sarli, V.; Panayiotidis, M.I.; Trafalis, D.T.
Azasteroid Alkylators as Dual Inhibitors of AKT and ERK Signaling for the Treatment of Ovarian Carcinoma. Cancers 2020, 12, 1263.
https://doi.org/10.3390/cancers12051263
AMA Style
Dalezis P, Geromichalou E, Polonifi A, Sagredou S, Nikoleousakos N, Nikolaou M, Sarli V, Panayiotidis MI, Trafalis DT.
Azasteroid Alkylators as Dual Inhibitors of AKT and ERK Signaling for the Treatment of Ovarian Carcinoma. Cancers. 2020; 12(5):1263.
https://doi.org/10.3390/cancers12051263
Chicago/Turabian Style
Dalezis, Panagiotis, Eleni Geromichalou, Aikaterini Polonifi, Sofia Sagredou, Nikolaos Nikoleousakos, Michael Nikolaou, Vasiliki Sarli, Mihalis I. Panayiotidis, and Dimitrios T. Trafalis.
2020. "Azasteroid Alkylators as Dual Inhibitors of AKT and ERK Signaling for the Treatment of Ovarian Carcinoma" Cancers 12, no. 5: 1263.
https://doi.org/10.3390/cancers12051263
APA Style
Dalezis, P., Geromichalou, E., Polonifi, A., Sagredou, S., Nikoleousakos, N., Nikolaou, M., Sarli, V., Panayiotidis, M. I., & Trafalis, D. T.
(2020). Azasteroid Alkylators as Dual Inhibitors of AKT and ERK Signaling for the Treatment of Ovarian Carcinoma. Cancers, 12(5), 1263.
https://doi.org/10.3390/cancers12051263